BNOS 2022 | LAT1 as a potential molecular target for glioblastoma

L-type amino acid transporter 1 (LAT1) is an amino acid symporter that transports amino acids as well as maintaining an amino acid gradient in cells. Kendall Morrison, PhD, TAE Life Sciences, Santa Monica, CA, discusses the rationale behind targeting LAT1 in glioblastoma. The protein is upregulated in tumor cells and boronated amino acids may make LAT1 a suitable target when treating glioblastoma with boron neutron capture therapy (BNCT). However not all patients may benefit from this due to tumor heterogeneity. This interview took place at the British Neuro-Oncology Society (BNOS) Annual Meeting 2022.